Steven R. Feldman MD, PhDProfessor of Dermatology, Pathology & Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Dr. Steve Feldman is Professor of Dermatology, Pathology & Public Health Sciences at the Wake Forest University School of Medicine. His research studies into patients’ adherence to topical treatments are transforming how physicians understand and manipulate patients’ use of treatment for chronic skin diseases. Dr. Feldman was the founder of www.DrScore.com, an online doctor rating/patient feedback website, and he is chief technology officer for Causa Research, a company that provides adherence improving services to industry. Feldman has authored over 600 peer reviewed medical articles. Dr. Feldman is a regular columnist for PM360 on adherence and author of the books Compartments and Practical Ways to Improve Patients’ Treatment Outcomes.
Dr. Steven Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.
Recent Contributions to PracticeUpdate:
- Association Between Atopic Eczema and Cancer
- Disseminated Coccidioidomycosis Treated With Interferon-γ and Dupilumab
- Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa
- The Frequency of Off-Label Prescribing in the Treatment of Dermatologic Disease
- Association Between Cycline Antibiotics and Development of Pseudotumor Cerebri Syndrome
- A Smartphone Application Supporting Patients With Psoriasis Improves Adherence to Topical Treatment
- Relationship Between Milk Consumption and Risk of Acne
- Continuous Every-2-Week Dosing of Ixekizumab Over 52 Weeks in Patients With Plaque Psoriasis
- Daily Aspirin Use May Be Associated With Increased Melanoma Risk in Men
- Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancer